Apellis Pharmaceuticals (NASDAQ: APLS) is one of 48 public companies in the “Biopharmaceuticals” industry, but how does it compare to its competitors? We will compare Apellis Pharmaceuticals to related companies based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, profitability, risk and dividends.
Valuation and Earnings
This table compares Apellis Pharmaceuticals and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Apellis Pharmaceuticals||N/A||-$27.12 million||-18.69|
|Apellis Pharmaceuticals Competitors||$631.32 million||$62.30 million||78.29|
Institutional and Insider Ownership
1.3% of Apellis Pharmaceuticals shares are held by institutional investors. Comparatively, 43.1% of shares of all “Biopharmaceuticals” companies are held by institutional investors. 14.9% of shares of all “Biopharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
This is a summary of current ratings and target prices for Apellis Pharmaceuticals and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Apellis Pharmaceuticals Competitors||172||845||1855||61||2.62|
Apellis Pharmaceuticals currently has a consensus price target of $27.00, indicating a potential upside of 80.60%. As a group, “Biopharmaceuticals” companies have a potential upside of 3.12%. Given Apellis Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Apellis Pharmaceuticals is more favorable than its competitors.
This table compares Apellis Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Apellis Pharmaceuticals Competitors||-13,490.78%||-54.37%||-24.83%|
Apellis Pharmaceuticals Company Profile
Apellis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company focuses on the discovery and development of therapeutic compounds for autoimmune and inflammatory diseases. The Company’s lead compounds are designed to inhibit complement component 3 (C3), the central protein in the complement cascade. The Company is developing APL-2 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) by subcutaneous injection, which is an injection into the tissue under the skin. It is developing APL-2 for the treatment of geographic atrophy (GA) and intermediate age-related macular degeneration (AMD) by intravitreal injection, which is an injection into the eye. The Company is developing APL-1 for the treatment of chronic obstructive pulmonary disease (COPD) by inhaled administration.
Receive News & Ratings for Apellis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Apellis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.